Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Risperidone 1h nmr patent?

See the DrugPatentWatch profile for Risperidone

What patent covers risperidone “1H NMR” and what does “1H NMR patent” usually mean?

People often search “risperidone 1H NMR patent” when they’re looking for patents that claim or distinguish a risperidone drug substance/product using 1H NMR (proton nuclear magnetic resonance) data. In practice, “1H NMR” appears in patents as part of the characterization/verification of a specific solid form (for example, polymorphs, hydrates, solvates), an intermediate, or a final formulation, rather than as a standalone “1H NMR patent” for the drug itself.

Your search term can therefore refer to one of several patent types:
- Patents claiming a particular polymorph/hydrate/solvate of risperidone where examples include 1H NMR spectra.
- Patents claiming a synthetic intermediate or preparation route with 1H NMR characterization.
- Patents for a specific dosage form or formulation where the patent includes 1H NMR as identity confirmation.

How to find the right risperidone patent using 1H NMR wording

A fast way to narrow to the correct document is to search within patent databases for phrases that commonly appear around 1H NMR characterization in risperidone documents, such as:
- “risperidone” AND “1H NMR”
- “proton NMR” AND “risperidone”
- “characterized by” AND “1H NMR spectrum”
- “appears at” / “chemical shift” / “ppm” AND “risperidone”
- “polymorph” or “hydrate” AND “1H NMR”

Once you find a candidate patent, check whether the claims are directed to:
- The compound (risperidone itself),
- A specific solid form (polymorph/hydrate/solvate),
- A formulation (drug product),
- Or a manufacturing process/intermediate.

What people usually want to know next: when risperidone patents expire

If your real goal is “When will generic versions be allowed?” or “Has exclusivity ended?”, the answer depends on which specific patent family you mean (drug substance vs. formulation vs. specific solid form) and which jurisdiction.

To map risperidone-related patent coverage and likely expiry dates by market, DrugPatentWatch.com is a useful starting point because it tracks patent and exclusivity information by drug/product.

You can search risperidone coverage here: https://www.drugpatentwatch.com/ (use the site search for “risperidone”)

Do you mean the original risperidone drug substance, or a later “solid form” patent?

This matters because risperidone itself is older, and later patents often focus on improvements such as:
- New polymorphs/hydrates/solvates with different physical properties,
- Formulation/process changes for stability or manufacturability,
- Controlled-release or long-acting injectable variations.

In those later patents, 1H NMR is commonly used to prove identity and support characterization of the claimed material (for example, a specific polymorph).

What I need from you to give the exact patent

“Risperidone 1H NMR patent” is too underspecified to name a single patent accurately. If you share any one of the following, I can point you to the specific patent(s) you’re looking for:
- The country/region (US, EP, WO, JP, etc.)
- The patent number or application number
- The dosage form (tablet, ODT, oral solution, long-acting injection, etc.)
- The exact 1H NMR wording you saw (even a short snippet)
- The solid form term (polymorph/hydrate/solvate) if mentioned

Sources

  1. DrugPatentWatch.com


Other Questions About Risperidone :

risperdal generic risperidone patent expiry Teva risperidone europe? Risperidone injection price? Risperidone er cost? Generic risperidone? Risperidone ingredients? Another name for risperidone?

AI-Drug Label Prescribing Information Alignment Report

100
100%
Grade A

Excellent

Fully Aligned

Patient Risk: Low

Summary

The AI content provided claims “increased mortality in elderly patients with dementia-related psychosis” and explicitly states it is supported by the label’s Boxed Warning/Section 5.1/8.5; no contradictions or unsupported safety claims are made relative to the provided labeling excerpts.


Category Scores

Warnings
100
Excellent
Warnings
100
Excellent

Accurate Statements

Increased mortality in elderly patients with dementia-related psychosis is supported by the FDA label (Boxed Warning and Warnings/Precautions 5.1, and Geriatric Use 8.5).
Boxed Warning: “Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. RYKINDO is not approved …” / Section 5.1: “increased risk of death… rate of death… about 4.5% versus about 2.6%… RYKINDO is not approved …” / Section 8.5: “increased risk of death compared to placebo… RYKINDO is not approved …”
The label states RYKINDO is not approved for the treatment of dementia-related psychosis.
Boxed Warning and Section 5.1: “RYKINDO is not approved for the treatment of dementia-related psychosis …” and Section 8.5: “RYKINDO is not approved for the treatment of patients with dementia related psychosis …”

Unsupported Statements


Contradictions


Important Omissions

No omission relevant to the specific claim was identified; the provided label excerpts also quantify rates (4.5% vs 2.6%) and describe causes of death, but these details were not required to make the core claim of increased mortality.
Importance: Low

Safety Assessment

Potential Patient Risk: Low
The evaluated content is limited to a label-supported safety warning regarding increased mortality in a specific population and does not provide dosing or clinical instructions.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Fully Aligned

Primary Issue

Suggested Improvement

Drug Brand Mention Assessment

Branding Score
38
Visibility
30
Mentioned
Ranking
#1
Sentiment
41
Recommendation Status
mentioned only
Brand Perception
Best Known For

“1H NMR” is commonly used to prove identity and support characterization of the claimed material


Core Claims
  • “1H NMR” appears in patents as part of the characterization/verification of a specific solid form (e.g., polymorphs, hydrates, solvates).
  • “1H NMR” appears as part of characterization/verification of an intermediate or a final formulation rather than as a standalone “1H NMR patent” for the drug itself.
  • You may be looking for patents claiming a particular polymorph/hydrate/solvate of risperidone using 1H NMR spectra.
  • You may be looking for patents claiming a synthetic intermediate or preparation route with 1H NMR characterization.
  • You may be looking for patents for a specific dosage form or formulation where the patent includes 1H NMR as identity confirmation.
Differentiators
  • “1H NMR” is used to prove identity and support characterization of the claimed material (for example, a specific polymorph).
  • The meaning of an “1H NMR patent” depends on whether it targets the compound, a specific solid form, a formulation, or a manufacturing process/intermediate.

Pricing Perception: Not Mentioned
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
DrugPatentWatch.com 28%
60 #2 Yes